For someone primarily focused on weight loss without specific cardiovascular concerns, tirzepatide's superior efficacy data may be more relevant
These are usually mild to moderate and typically appear when treatment starts or the dose is increased
GLP-1 Receptor Activation Metabolic Regulation GLP2 activates GLP-1 receptors with lower potency than endogenous GLP-1 but demonstrates biased signaling properties: Preferential cAMP pathway activation over beta-arrestin recruitment, which may enhance insulin secretory responses Suppression of inappropriately elevated glucagon secretion during hyperglycemia Reduced GLP-1 receptor internalization compared to native GLP-1, potentially extending signaling duration Contribution to glucose-dependent insulin secretion complementary to GIP receptor effects Research in isolated pancreatic islets demonstrated that GLP2s insulinotropic actions depend on GIP receptor presence, with the biased GLP-1 receptor signaling providing synergistic enhancement
The REDEFINE 2 trial examined CagriSema in adults with type 2 diabetes, a population that typically shows less weight loss with GLP-1 therapies
The addition of glucagon receptor agonism introduces a third axis: increased energy expenditure, enhanced hepatic fat oxidation, and PCSK9-mediated reduction in LDL cholesterol
This regain reflects biology rather than willpower failure
